Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jamie Cameron

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Molecular Genetics and Metabolism Reports|November 30, 2016
Studies of the autoinhibitory segment comprising residues 31-60 of the prodomain of PCSK9: Possible implications for the mechanism underlying gain-of-function mutationsLene Wierød, Jamie Cameron, Thea Bismo Strøm, et al.
Fundamental & Clinical Pharmacology|December 14, 2021
Characteristics, treatment patterns, and residual cardiovascular risk of patients with a first acute myocardial infarction: A nationwide population-based cohort study in NorwayNikolaus G Oberprieler, Bahman Farahmand, Jamie Cameron, et al.
Atherosclerosis|March 22, 2008
Berberine decreases PCSK9 expression in HepG2 cellsJamie Cameron, Trine Ranheim, Mari Ann Kulseth, et al.
Atherosclerosis|October 30, 2012
Mutations in the SORT1 gene are unlikely to cause autosomal dominant hypercholesterolemiaKristian Tveten, Thea Bismo Strøm, Jamie Cameron, et al.
BMC Cell Biology|March 3, 2007
Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularlyØystein L Holla, Jamie Cameron, Knut Erik Berge, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|April 14, 2009
Splice-site mutation c.313+1, G>A in intron 3 of the LDL receptor gene results in transcripts with skipping of exon 3 and inclusion of intron 3Jamie Cameron, Øystein L Holla, Mari Ann Kulseth, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 18, 2009
Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotesThea Bismo Strøm, Øystein L Holla, Jamie Cameron, et al.
Molecular Genetics and Metabolism|October 16, 2009
A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9Øystein L Holla, Thea Bismo Strøm, Jamie Cameron, et al.
Atherosclerosis|September 22, 2009
Tangier disease caused by compound heterozygosity for ABCA1 mutations R282X and Y1532CJamie Cameron, Trine Ranheim, Bente Halvorsen, et al.
International Journal of Law and Psychiatry|March 13, 2022
Privacy and safety: Issues of dual compliance in high-secure and other forensic psychiatric hospitalsJamie Cameron, Matti Thurlin, N Zoe Hilton, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Molecular Genetics and Metabolism Reports|November 30, 2016
Studies of the autoinhibitory segment comprising residues 31-60 of the prodomain of PCSK9: Possible implications for the mechanism underlying gain-of-function mutationsLene Wierød, Jamie Cameron, Thea Bismo Strøm, et al.
Fundamental & Clinical Pharmacology|December 14, 2021
Characteristics, treatment patterns, and residual cardiovascular risk of patients with a first acute myocardial infarction: A nationwide population-based cohort study in NorwayNikolaus G Oberprieler, Bahman Farahmand, Jamie Cameron, et al.
Atherosclerosis|March 22, 2008
Berberine decreases PCSK9 expression in HepG2 cellsJamie Cameron, Trine Ranheim, Mari Ann Kulseth, et al.
Atherosclerosis|October 30, 2012
Mutations in the SORT1 gene are unlikely to cause autosomal dominant hypercholesterolemiaKristian Tveten, Thea Bismo Strøm, Jamie Cameron, et al.
BMC Cell Biology|March 3, 2007
Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularlyØystein L Holla, Jamie Cameron, Knut Erik Berge, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|April 14, 2009
Splice-site mutation c.313+1, G>A in intron 3 of the LDL receptor gene results in transcripts with skipping of exon 3 and inclusion of intron 3Jamie Cameron, Øystein L Holla, Mari Ann Kulseth, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 18, 2009
Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotesThea Bismo Strøm, Øystein L Holla, Jamie Cameron, et al.
Molecular Genetics and Metabolism|October 16, 2009
A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9Øystein L Holla, Thea Bismo Strøm, Jamie Cameron, et al.
Atherosclerosis|September 22, 2009
Tangier disease caused by compound heterozygosity for ABCA1 mutations R282X and Y1532CJamie Cameron, Trine Ranheim, Bente Halvorsen, et al.
International Journal of Law and Psychiatry|March 13, 2022
Privacy and safety: Issues of dual compliance in high-secure and other forensic psychiatric hospitalsJamie Cameron, Matti Thurlin, N Zoe Hilton, et al.
Pageof 3